Reporting owner · Q3 2026 · CIK 1191702

Moore John R: insider trades.

Moore John R reported 6 non-derivative transactions on 2 SEC ownership filings in Q3 2026: 0 open-market purchases and 4 sales ($220K), across 1 company.

Transactions
6
Purchases (P)
0
Sales (S)
4
Companies
1
Name as filed
MOORE JOHN R

Companies

CompanyRelationshipTransactions
Edgewise Therapeutics, Inc. (EWTX)Officer · General Counsel6

Transactions

6 non-derivative rows. Shares and prices as filed.
DateCompanyCodeSharesPriceOwned afterFiling
2026-08-12Edgewise Therapeutics, Inc.S2,439$43.8120,274Form 4
2026-08-12Edgewise Therapeutics, Inc.M6,718$022,713Form 4
2026-08-12Edgewise Therapeutics, Inc.S59$44.4120,215Form 4
2026-08-12Edgewise Therapeutics, Inc.S99$44.520,116Form 4
2026-08-12Edgewise Therapeutics, Inc.S2,419$43.817,697Form 4
2026-08-12Edgewise Therapeutics, Inc.M5,781$015,995Form 4

Questions

What stock did Moore John R buy or sell?

Moore John R reported 6 non-derivative transactions on 2 SEC ownership filings in Q3 2026: 0 open-market purchases and 4 sales ($220K), across 1 company.

Is Moore John R the same person as other filers with this name?

This page covers SEC CIK 1191702 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.

Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.

Plain-text version for agents and LLMs: /insiders/moore-john-r-1191702.md

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.